KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Liabilities (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Total Liabilities for 17 consecutive years, with $32.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 2.29% year-over-year to $32.8 billion, compared with a TTM value of $32.8 billion through Dec 2025, down 2.29%, and an annual FY2025 reading of $32.8 billion, down 2.29% over the prior year.
  • Total Liabilities was $32.8 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $32.6 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $38.0 billion in Q1 2021 and bottomed at -$6.6 billion in Q2 2024.
  • Average Total Liabilities over 5 years is $33.0 billion, with a median of $35.3 billion recorded in 2022.
  • The sharpest move saw Total Liabilities plummeted 118.55% in 2024, then soared 607.34% in 2025.
  • Year by year, Total Liabilities stood at $36.4 billion in 2021, then fell by 3.04% to $35.3 billion in 2022, then grew by 0.11% to $35.4 billion in 2023, then dropped by 4.94% to $33.6 billion in 2024, then fell by 2.29% to $32.8 billion in 2025.
  • Business Quant data shows Total Liabilities for TEVA at $32.8 billion in Q4 2025, $32.6 billion in Q3 2025, and $33.3 billion in Q2 2025.